Literature DB >> 7895562

Relationship between gastroprotective effect of locally acting antiulcer agent ecabet sodium and its binding to gastric mucosa in rats. Comparison with sucralfate.

M Kinoshita1, K Yamasaki, Y Kokusenya, H Tamaki.   

Abstract

The present study was designed to examine the relationship between the gastroprotective efficacy of the locally acting antiulcer drug ecabet sodium (ecabet) against ethanol-induced gastric lesions and the amount of the drug bound to the mucosa in comparison with sucralfate in rats. Oral administration of ecabet (25-100 mg/kg) and sucralfate (25-400 mg/kg) dose dependently prevented the formation of ethanol-induced gastric lesions, and dose dependently increased the amount of each drug bound to the gastric mucosa. Pretreatment with the antisecretory agent cimetidine (200 mg/kg, per os) significantly reduced the gastroprotective effect of sucralfate in proportion to a decrease in its binding to the mucosa. The same pretreatment tended to reduce both gastroprotection by ecabet and its binding to the mucosa. In an in vitro study using an everted stomach sac, the binding of sucralfate to the mucosa was more markedly decreased than that of ecabet on increasing the pH. These findings indicate that ecabet and sucralfate protect the gastric mucosa against ethanol in proportion to the amount of each drug bound to the gastric mucosa and that the binding of these drugs to the mucosa is under the influence of intraluminal pH. However, the gastroprotective effect of ecabet seems to be less dependent on intraluminal acidity than that of sucralfate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7895562     DOI: 10.1007/bf02064387

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  20 in total

Review 1.  The protective and therapeutic mechanisms of sucralfate.

Authors:  D Hollander; A Tarnawski
Journal:  Scand J Gastroenterol Suppl       Date:  1990

2.  Effects of the new anti-ulcer drug ecabet sodium (TA-2711) on pepsin activity. II. Interaction with substrate protein.

Authors:  Y Ito; Y Onoda; S Nakamura; K Tagawa; T Fukushima; Y Sugawara; O Takaiti
Journal:  Jpn J Pharmacol       Date:  1993-06

3.  Selective binding of sucralfate to ulcer lesion. I. Experiments in rats with acetic acid-induced gastric ulcer receiving unlabelled sucralfate.

Authors:  R Nagashima; T Hirano
Journal:  Arzneimittelforschung       Date:  1980

4.  Effects of 12-sulfodehydroabietic acid monosodium salt (TA-2711), a new anti-ulcer agent, on gastric secretion and experimental ulcers in rats.

Authors:  Y Onoda; T Magaribuchi; H Tamaki
Journal:  Jpn J Pharmacol       Date:  1989-09

5.  Sucralfate and soluble sucrose octasulfate bind and stabilize acidic fibroblast growth factor.

Authors:  D B Volkin; A M Verticelli; K E Marfia; C J Burke; H Mach; C R Middaugh
Journal:  Biochim Biophys Acta       Date:  1993-11-10

6.  Gastrocytoprotection by colloidal bismuth subcitrate (De-Nol) and sucralfate. Role of endogenous prostaglandins.

Authors:  S J Konturek; T Radecki; I Piastucki; T Brzozowski; D Drozdowicz
Journal:  Gut       Date:  1987-02       Impact factor: 23.059

7.  Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.

Authors:  H Nagaya; N Inatomi; H Satoh
Journal:  Jpn J Pharmacol       Date:  1991-04

8.  Development and characteristics of sucralfate.

Authors:  R Nagashima
Journal:  J Clin Gastroenterol       Date:  1981       Impact factor: 3.062

9.  Effects of an antiulcer drug, sucralfate (a basic aluminum salt of sulfated disaccharide), on experimental gastric lesions and gastric secretion in rats.

Authors:  S Okabe; K Takeuchi; H Kunimi; M Kanno; M Kawashima
Journal:  Dig Dis Sci       Date:  1983-11       Impact factor: 3.199

10.  Selective binding of sucralfate to gastric ulcer in man.

Authors:  S Nakazawa; R Nagashima; I M Samloff
Journal:  Dig Dis Sci       Date:  1981-04       Impact factor: 3.199

View more
  3 in total

1.  Safety and tolerability of bismuthyl ecabet suspension, a novel anti-ulcer agent, following single and multiple oral dose administration in healthy Chinese subjects.

Authors:  Yongqing Wang; Nana Tang; Ling Meng; Peipei Zhang; Kun Xu; Ningling Jiang; Haibo Zhang; Ning Ou; Deqin Wu; Anjiu Chen; Xiyong Zhang; Ruihua Shi
Journal:  Clin Drug Investig       Date:  2012-04-01       Impact factor: 2.859

2.  Efficacy and safety of ecabet sodium on functional dyspepsia: a prospective, double-blinded, randomized, multi-center controlled trial.

Authors:  Jun Haeng Lee; Jae J Kim; Ki-Baik Hahm; Dong Ho Lee; Nayoung Kim; Sung Kook Kim; Jong Jae Park; Seok Reyol Choi; Jong Hun Lee; Soo Teik Lee; Eun Hyun Lee; Jong Chul Rhee
Journal:  World J Gastroenterol       Date:  2006-05-07       Impact factor: 5.742

3.  Characteristic pathological findings and effects of ecabet sodium in rat reflux esophagitis.

Authors:  Daisuke Asaoka; Akihito Nagahara; Masako Oguro; Yuko Izumi; Akihiko Kurosawa; Taro Osada; Masato Kawabe; Mariko Hojo; Michiro Otaka; Sumio Watanabe
Journal:  World J Gastroenterol       Date:  2009-07-28       Impact factor: 5.742

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.